Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCUTIO
2023-508831-29-00Phase 2Completed
- Sponsor
- MyoKardia
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of BMS-986435 in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by MyoKardia. Primary endpoints: Incidence, severity, and causality of adverse events and serious adverse events, Incidence of symptomatic resting left ventricular ejection fraction below 50% and 8 more. Started Mar 2024; status: completed.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2023-508831-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508831-29-00.